Category: ARC News

Dale Schenk was born May 10, 1957 in Glendora, California to Walter Bernard Schenk, a firefighter, and Rosemary Schenk, a family therapist. He received an undergraduate degree in biology in 1979 from the University of California at San Diego, where...

Amyloidosis Research Consortium Announces Publication of Seminal Manuscript in Peer-Reviewed Journal Leukemia Encouraging Use of NT-proBNP as Endpoint in Clinical Trials. International AL amyloidosis expert community agrees N-terminal pro-brain natriuretic peptide (NT-proBNP) is analytically validated and clinically qualified to be...

We are pleased to announce the launch of the ARC's Amyloidosis Clinical Resources App for healthcare professionals.  This new app contains comprehensive disease overviews, diagnostic tools and current treatment protocols for the main types of amyloidosis as well as resources for...

To highlight amyloidosis during rare disease week this year Isabelle Lousada, president and CEO of the Amyloidosis Research Consortium, was invited to provide a guest blog for PhRMA publication The Catalyst. Isabelle talks about the experiences that led her to...

On 23rd February 2016, under the leadership of Mike Zelin, the ARC’s Director of Industry Relations, we held the first meeting of the ARC Industry Advisory Council. This groundbreaking meeting brought together key leaders from seven pharmaceutical companies. These companies...